 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Azilect, Azipron, others |
| Other names | VP-1012, N-propargyl-1(R)-aminoindan[1] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606017 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Monoamine oxidase-B inhibitor[2] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 36% |
| Protein binding | 88 – 94% |
| Metabolism | Liver (CYP1A2-mediated) |
| Elimination half-life | 3 hours[citation needed] |
| Excretion | Kidney and fecal |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C12H13N |
| Molar mass | 171.243 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Rasagiline, sold under the brand name Azilect among others, is a medication used to treat symptoms in Parkinson's disease.[2] It may be used alone or together with other medication.[2] It is taken by mouth.[2]
Common side effects include joint pain, indigestion, depression, trouble sleeping, swelling, and nausea.[3] Other side effects may include high blood pressure, serotonin syndrome, sleepiness, compulsive gambling, and hallucinations.[3] Safety in pregnancy and breastfeeding is unclear.[5] It is an irreversible inhibitor of monoamine oxidase-B.[2]
Rasagiline was developed in the early 1979 and approved for medical use in Europe in 2005 and the United States in 2006.[6][2][7] It is available as a generic medication.[4] In the United Kingdom 4 weeks of medication costs the NHS about £2.50.[4]
References edit
- ^ Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (June 2002). "An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells". Neuroscience Letters. 326 (2): 105–8. doi:10.1016/s0304-3940(02)00332-4. PMID 12057839. S2CID 29736753.
- ^ a b c d e f g "Rasagiline Monograph for Professionals". Drugs.com. Archived from the original on 1 May 2021. Retrieved 16 October 2021.
- ^ a b c "DailyMed - RASAGILINE MESYLATE tablet". dailymed.nlm.nih.gov. Archived from the original on 28 March 2021. Retrieved 16 October 2021.
- ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 446. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Rasagiline (Azilect) Use During Pregnancy". Drugs.com. Archived from the original on 24 October 2020. Retrieved 16 October 2021.
- ^ "Azilect". Archived from the original on 10 January 2021. Retrieved 16 October 2021.
- ^ Stolberg, Victor B. (27 October 2017). ADHD Medications: History, Science, and Issues. ABC-CLIO. p. 82. ISBN 978-1-61069-726-2. Archived from the original on 16 October 2021. Retrieved 16 October 2021.